Key facts
- Xanadu Bio’s last known valuation is $90.0M (Aug 2025).
- It has raised $23.0M across 2 recorded rounds; the latest was Early Stage VC ($11.0M) in Aug 2025.
- Xanadu Bio has filed 2 Form Ds with the SEC since 2022, most recently Aug 2025 ($11.0M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Xanadu Bio
Funding rounds
2 roundsAbout Xanadu Bio
Operator of a nanoparticle delivery platform intended to offer delivery of mRNA and other nucleic acids. The company's platform utilizes PACE platform technology that consists of three monomers that are fully biodegradable and allow for efficient delivery of and protection from nuclease degradation for different types of nucleic acids, enabling the medical system to access cost-effective and scalable technology that can be functionalized to allow both organ and cell-specific delivery of its nucleic acid payload.
- Sector
- Healthcare
- HQ
- Gladwyne, PA, United States
- Founded
- 2021
- Employees
- 7
- Website
- xanadubio.com/
- Ownership
- Privately Held (backing)
Xanadu Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xanadu Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xanadu Bio in its N-PORT filings yet. We sweep new filings monthly.